R&D discussion in New York City to test the potential of IL-12 to treat ovarian cancer
The program includes leading experts in the field of ovarian cancer, researchers from the OVATION 2 study, and oncology experts.
LAWRENCEVILLE, NJ, Aug. 28, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a late-stage clinical-stage company with its DNA-mediated immunotherapy, invites investors to mark their calendars for R&D Day on September 18 at the Harvard Club in New York City.th from 10:00 a.m. to 1:00 p.m. Eastern Time.
The R&D Day follows Imunon’s announcement of key data from its randomized Phase II Ovation 2 trial. These data indicate an increase in median OS of 11.1 months in the intent-to-treat population, representing a remarkable 35% improvement in survival in patients with advanced ovarian cancer.
The program will feature leading ovarian cancer experts, principal investigators of the company’s Phase 2 OVATION-2 trial of IMNN-001, an overview of the study’s key findings and how the data will feed into the Phase 3 registrational trial, and a discussion of IMNN-001’s potential role in treating advanced ovarian cancer. In addition, management will discuss next steps with its powerful immunotherapy and the prospects for extending patient survival.
We strongly encourage in-person attendance to facilitate networking and direct interaction with our speakers and management team, but for those unable to attend in person, virtual participation is also available.
Details of the program, including speakers, will be announced shortly, as will the opportunity to confirm your participation.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to deliver safe, effective and durable responses to a broad range of human diseases, providing an approach that is different from conventional therapies. IMUNON is developing its non-viral DNA technology across all of its modalities. The first modality, TheraPlas®is being developed for the encoding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is considered promising. The second modality, PlaCCine®was developed for the delivery of DNA-encoded viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 clinical trials. IMNN-001 works by directing the body to produce safe and sustained levels of potent cancer-fighting molecules such as interleukin-12 and interferon-gamma at the tumor site. In addition, the Company has initiated a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and push the technological frontier of plasmid DNA to better serve patients with difficult-to-treat diseases. For more information, visit www.imunon.com.
Contacts:
# # #
